ProCE Banner Activity

ARASENS: Post Hoc Analysis of Outcomes by Disease Volume and Risk With Darolutamide vs Placebo in Combination With ADT + Docetaxel in Metastatic HSPC

Capsule Summary
Conference Coverage

The addition of darolutamide to ADT and docetaxel for mHSPC provided a significant OS benefit and improvements in multiple clinical secondary endpoints regardless of disease volume or risk status.

Released: February 22, 2023

Expiration: February 21, 2024


Provided by

ProCE Banner


This activity is supported by educational grants from

Bayer HealthCare Pharmaceuticals Inc.

Exelixis, Inc.

Gilead Sciences, Inc.

Pfizer, Inc.